JCR Pharmaceuticals, Takeda discontinue gene therapy collaboration
Initially established on 28 March 2022, the agreement between JCR and Takeda focused on joint research and development…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Dec 23
Initially established on 28 March 2022, the agreement between JCR and Takeda focused on joint research and development…
21 Dec 23
Since its establishment in 2020, the Indiana-based biopharmaceutical company has raised a total of $157m funding, with $37m…
20 Dec 23
The joint research venture entitled, New Strategies to Engage Neutrophils in Solid Tumors, is intended to develop immunotherapies…
20 Dec 23
V116, which is intended to be administered as a single dose, is designed to specifically mitigate the risk…
20 Dec 23
The primary application of CorEvidence focuses on improving pharmacovigilance workflows and managing deliverables more effectively
20 Dec 23
Qelbree is a commercially available prescription medication in the US to treat ADHD and Supernus has granted Knight…
20 Dec 23
COM503 is a potential first-in-class, high affinity antibody that inhibits the progression of cancer by releasing endogenous IL-18…
19 Dec 23
Otsuka will acquire exclusive rights to market donidalorsen in Europe in exchange for an upfront payment of $65m,…
19 Dec 23
Manufactured from pooled human plasma from American donors, Alyglo is a liquid solution with 10% immunoglobulin G (100…
19 Dec 23
The late-stage trial assessed the combination against placebo plus chemotherapy followed by placebo and the combination met the…